See also
Windows 10
Microsoft Windows
References
Category:Windows security software
Category:Windows-only software
Category:FreewareFree medical follow up in primary health care.
A study is presented of patients who have been observed and treated in a primary health care center in the city of Osorno, during a period of three months. The objective of the study is to review the data obtained regarding the care given to the patients and to determine whether this type of approach is a valid alternative for the health care currently in use in our country. Twenty-four (14 men and 10 women) patients have been studied. The sample was selected from those patients who consulted for the first time in the center, without having been seen previously by a doctor. The analysis shows that many patients come to the center with complications or diseases and have consequently to receive detailed medical care. Patients who had an active consultation by the family doctor before they were admitted to the center were more frequently reevaluated by him after being treated there. This practice was done in order to improve the treatment and to prevent any possible recurrence of the illness. It is concluded that the follow-up of patients in the primary health care center has proved to be useful and effective.1. Field of the Invention
The present invention relates to the discovery of two different types of tumor-inducing transforming growth factor beta's (TGF.beta.) which are produced by a novel, more commonly-expressed TGF.beta. type II gene. The first of these two novel TGF.beta.'s (called TGF.beta.II) is normally not expressed in mammary epithelial cells. Its production is markedly stimulated by the presence of certain breast carcinoma cells. This TGF.beta.II is also found to have a role in breast cancer, since it has been found that it is able to suppress the growth of mammary epithelial cells. In a parallel manner, the other TGF.beta., which is normally expressed, is found to be active in stimulating the growth of mammary epithelial cells. This other TGF.beta. is also found to be one of the TGF.beta.'s expressed in breast cancers, and thus one of the TGF.beta.'s present in breast cancer serum. Furthermore, this TGF.beta. is found to have growth suppressive activity in mammary epithelial cells. Both of these TGF.beta.'s can be used to diagnose breast cancer, and also be359ba680
Related links:
Comments